Pharma execs raise concerns about Trump’s plans for the FDA; Merck ends study of experimental Alzheimer’s drug; Amgen seeks new indication for Blincyto
Five things for pharma marketers to know: Wednesday, January 18, 2017
Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz’s Xyrem
Five things for pharma marketers to know: Friday, January 13, 2017
Pfizer to start selling Remicade biosimilar in November; The Medicines Co.’s PCSK9 inhibitor heads to Phase-III trials; J&J’s Q3 growth bolstered by autoimmune drugs
Five things for pharma marketers to know: Friday, October 14, 2016
More drugmakers file lawsuits to prevent biosimilar competition; experimental dermatitis drug showeds promising results; pharma blames PBMs for price hikes
The FDA approves Amgen’s biosimilar version of Humira
Court clears Pfizer to move ahead with Remicade biosimilar; McDonald’s yanks activity trackers over skin irritation; California drug-pricing bill pulled